To contentTo navigationTo search
Logotype

Investors

Press releases

Press releases

2021

Bulletin from the Annual General Meeting in Implantica AG

16.04.2021
 | Inside information
Today, April 16, 2021, the annual general meeting (the “AGM”) of Implantica AG (publ) was held in Vaduz. The general meeting resolved to adopt all of the board of directors’ resolution proposals. A summary of the resolutions adopted at the general meeting is set out below.

Implantica har beslutat att gå vidare med en riktad nyemission av svenska depåbevis som tillför bolaget cirka 600 miljoner SEK

16.04.2021
 | Inside information
Implantica AG (ticker: IMP A SDB) (”Implantica” eller ”Bolaget”) har beslutat att gå vidare med en riktad nyemission om 4 900 000 nyutgivna A-aktier representerade av svenska depåbevis (”SDB”) till en teckningskurs om 122,20 SEK per SDB (den ”Riktade Nyemissionen”). Den Riktade Nyemissionen är villkorad av att styrelsen formellt beslutar om den Riktade Nyemissionen, baserat på ett bemyndigande som väntas ges på årsstämman som hålls den 16 april 2021 (”Årsstämman”). Teckningskursen i den Riktade Nyemissionen fastställdes genom ett accelererat bookbuilding-förfarande utfört av Pareto Securities (”Sole Global Coordinator och Bookrunner”). Den Riktade Nyemissionen var flera gånger övertecknad och tilldelades ett antal nya och befintliga institutionella investerare, däribland DNCA Investments, Handelsbanken Fonder, Invus, Swedbank Robur Fonder och TIN Fonder.   

Implantica has decided to proceed with a private placement of SDRs raising gross proceeds of approximately SEK 600 million

15.04.2021
 | Inside information
Implantica AG (ticker: IMP A SDB) (“Implantica” or the “Company”) has decided to proceed with a private placement of 4,900,000 newly issued Class A shares represented by Swedish Depository Receipts (“SDRs”) at a subscription price of SEK 122.20 per SDR (the “Private Placement”). The Private Placement is subject to the board of directors formally resolving on the Private Placement following the authorization to be granted by the Annual General Meeting (the “AGM”) on 16 April 2021. The subscription price per SDR in the Private Placement was determined through an accelerated book building procedure conducted by Pareto Securities AB (the “Sole Global Coordinator and Bookrunner”). The Private Placement was multiple times over-subscribed and was directed to a number of new and existing institutional investors, including DNCA Investments, Handelsbanken Fonder, Invus, Swedbank Robur Fonder and TIN Fonder.

Implantica avser genomföra en riktad nyemission av svenska depåbevis

15.04.2021
 | Inside information
Implantica AG (ticker: IMP A SDB) (”Implantica” eller ”Bolaget”) har gett i uppdrag till Pareto Securities att utvärdera möjligheterna att genomföra en riktad nyemission av svenska depåbevis (”SDB”) om cirka 500 miljoner SEK (den ”Riktade Nyemissionen”) till svenska och internationella institutionella investerare genom ett accelererat bookbuilding-förfarande.

Implantica contemplates a private placement of SDRs

15.04.2021
 | Inside information
Implantica AG (ticker: IMP A SDB) (“Implantica” or the “Company”) has mandated Pareto Securities to evaluate the conditions for a private placement of SDRs corresponding to approximately SEK 500 million (the “Private Placement”), to Swedish and international institutional investors through an accelerated book building procedure.

Notice of Annual General Meeting of Implantica AG

29.03.2021
 | Inside information
The shareholders of Implantica AG (publ), reg. no. FL-0002.629.889-3, are hereby given notice of the annual general meeting on Friday, April 16, 2021, at 11:00 CET.

Implantica publishes Annual Report 2020

24.03.2021
 | Inside information
Implantica AG (publ) is publishing its annual report for the fiscal year 2020. The annual report is now available on the company’s website.

Implantica publicerar årsredovisning 2020

24.03.2021
 | Inside information
Implantica AG (publ) publicerar sin årsredovisning för räkenskapsåret 2020. Årsredovisningen finns nu tillgänglig på bolagets hemsida.

Implantica announces a milestone achieved for its implantable medical device RefluxStop™

23.03.2021
 | Other press releases
Implantica AG (publ) today announces that one of the largest hospitals in Europe, University Hospital AKH Vienna, will soon commence a study of RefluxStop™ with 25-30 reflux patients, conducted under the direction of Prof. Dr. med. Sebastian Schoppmann.

Implantica meddelar att en milstolpe uppnåtts för deras medicinska implantat RefluxStop™

23.03.2021
 | Other press releases
Implantica AG (publ) offentliggör idag att ett av Europas största Universitetssjukhus, AKH Wien, kommer snart påbörja en studie av RefluxStop™ omfattande 25-30 reflux patienter, utförda under ledning av Prof. Dr. med. Sebastian Schoppmann.
Load more

This website uses cookies to provide the best possible user experience. If you continue without making any changes you allow this. Read more about cookies here